In vitro activity of oral antibiotics against extensively drug-resistant Shigella isolates: a pharmacokinetic/pharmacodynamic perspective on the intracellular pathogenesis paradigm

Introduction. Shigellosis is emerging as a critical therapeutic challenge in low- and middle-income countries (LMICs) due to the emergence of extensively drug-resistant (XDR) strains resistant to azithromycin, third-generation cephalosporins and fluoroquinolones. The obligate intracellular lifestyle of Shigella , characterized by epithelial cell invasion and actin-mediated intracellular spread, limits the predictive value of conventional extracellular susceptibility testing alone. Hypothesis/Gap Statement. The loss of effective oral antibiotics for XDR Shigella represents a major unmet clinical and public health need, particularly in endemic LMIC settings where outpatient management is essential. Current breakpoint-based susceptibility interpretations primarily reflect extracellular antimicrobial exposure and may inadequately capture the intracellular pharmacodynamic requirements of Shigella infection. Furthermore, integrated evaluation of in vitro susceptibility together with pharmacokinetic–pharmacodynamic (PK/PD) and intracellular exposure parameters for candidate oral agents against XDR Shigella remains limited. Aim. To evaluate the molecular resistance profiles, in vitro activity and PK/PD applicability of candidate oral antibiotics against XDR Shigella isolates. Methodology. Between 2010 and March 2025, 1,823 non-duplicate clinical Shigella isolates were screened at a tertiary care centre in South India. Fifty-two isolates fulfilled XDR criteria: azithromycin MIC ≥32 mg l −1 , ceftriaxone MIC >4 mg l −1 and ciprofloxacin MIC >1 mg l −1 . PCR assays targeted blaCTX-M , blaDHA , blaCMY , blaVIM , blaNDM , mphA , msrE , ermB , qnrS and qnrB . MICs for amoxicillin–clavulanate, cefpodoxime–clavulanate, fosfomycin, mecillinam and faropenem were determined using broth or agar dilution methods and interpreted using Clinical and Laboratory Standards Institute (CLSI) M100 (2025) or literature-derived PK/PD thresholds. Results. β -Lactamase genes and mphA were detected in 96.2% of isolates, whilst qnrS / qnrB occurred in 53.8%. Cefpodoxime–clavulanate and faropenem showed 100% susceptibility, followed by fosfomycin (98.1%) and mecillinam (94.2%). MIC50/MIC90 (mg l −1 ) were 0.5/0.5 for faropenem, 0.25/2 for mecillinam and 0.25/2 for cefpodoxime–clavulanate. However, PK/PD analysis suggested that several agents lacked sustained intracellular exposure despite favourable MICs. Conclusion. Favourable in vitro susceptibility did not consistently translate into predicted intracellular therapeutic adequacy. These findings support PK/PD-informed assessment beyond MIC-based interpretation for managing XDR shigellosis and highlight the urgent need for effective oral therapeutic options for XDR Shigella infections

Authors

Institutions

Publication Details

Journal
Journal of Medical Microbiology
Published
2026-11-13
DOI
https://doi.org/10.1099/jmm.0.002213
Primary Topic
Antibiotic Resistance in Bacteria
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

In vitro activity of oral antibiotics against extensively drug-resistant Shigella isolates: a pharmacokinetic/pharmacodynamic perspective on the intracellular pathogenesis paradigm

Kāmini Walia, Yamuna Devi Bakthavatchalam, Madhumathi Irulappan, Balaji Veeraraghavan et al.
2 links
Journal of Medical Microbiology
Antibiotic Resistance in Bacteria
article

In vitro activity of oral antibiotics against extensively drug-resistant Shigella isolates: a pharmacokinetic/pharmacodynamic perspective on the intracellular pathogenesis paradigm

Kāmini Walia, Yamuna Devi Bakthavatchalam, Madhumathi Irulappan, Balaji Veeraraghavan, Shariqa Qureshi, Baby Abirami, Karnan Selvam, Ramprakash Rayala, Venkatalakshmipriya G, Ekadashi Rajni Sabharwal, Dhanalakshmi Solamalai, Sridhar P, Nivedana S
article en

Abstract

Introduction. Shigellosis is emerging as a critical therapeutic challenge in low- and middle-income countries (LMICs) due to the emergence of extensively drug-resistant (XDR) strains resistant to azithromycin, third-generation cephalosporins and fluoroquinolones. The obligate intracellular lifestyle of Shigella , characterized by epithelial cell invasion and actin-mediated intracellular spread, limits the predictive value of conventional extracellular susceptibility testing alone. Hypothesis/Gap Statement. The loss of effective oral antibiotics for XDR Shigella represents a major unmet clinical and public health need, particularly in endemic LMIC settings where outpatient management is essential. Current breakpoint-based susceptibility interpretations primarily reflect extracellular antimicrobial exposure and may inadequately capture the intracellular pharmacodynamic requirements of Shigella infection. Furthermore, integrated evaluation of in vitro susceptibility together with pharmacokinetic–pharmacodynamic (PK/PD) and intracellular exposure parameters for candidate oral agents against XDR Shigella remains limited. Aim. To evaluate the molecular resistance profiles, in vitro activity and PK/PD applicability of candidate oral antibiotics against XDR Shigella isolates. Methodology. Between 2010 and March 2025, 1,823 non-duplicate clinical Shigella isolates were screened at a tertiary care centre in South India. Fifty-two isolates fulfilled XDR criteria: azithromycin MIC ≥32 mg l −1 , ceftriaxone MIC >4 mg l −1 and ciprofloxacin MIC >1 mg l −1 . PCR assays targeted blaCTX-M , blaDHA , blaCMY , blaVIM , blaNDM , mphA , msrE , ermB , qnrS and qnrB . MICs for amoxicillin–clavulanate, cefpodoxime–clavulanate, fosfomycin, mecillinam and faropenem were determined using broth or agar dilution methods and interpreted using Clinical and Laboratory Standards Institute (CLSI) M100 (2025) or literature-derived PK/PD thresholds. Results. β -Lactamase genes and mphA were detected in 96.2% of isolates, whilst qnrS / qnrB occurred in 53.8%. Cefpodoxime–clavulanate and faropenem showed 100% susceptibility, followed by fosfomycin (98.1%) and mecillinam (94.2%). MIC50/MIC90 (mg l −1 ) were 0.5/0.5 for faropenem, 0.25/2 for mecillinam and 0.25/2 for cefpodoxime–clavulanate. However, PK/PD analysis suggested that several agents lacked sustained intracellular exposure despite favourable MICs. Conclusion. Favourable in vitro susceptibility did not consistently translate into predicted intracellular therapeutic adequacy. These findings support PK/PD-informed assessment beyond MIC-based interpretation for managing XDR shigellosis and highlight the urgent need for effective oral therapeutic options for XDR Shigella infections

Journal of Medical MicrobiologyVol. 75(11)
Christian Medical College, Vellore (IN), Indian Council of Medical Research (IN), Rainbow Children's Hospital (IN), Chacha Nehru Bal Chikitsalaya (IN)
Indian Council of Medical Research
Good health and well-being
Antibiotic Resistance in Bacteria
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon